VIROPHARMA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of ViroPharma Inc. (VPHM) Over the Proposed Sale of the Company to Shire (SHPG) in a Cash Deal
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of ViroPharma Inc. (“ViroPharma” or the “Company”) (NasdaqGS: VPHM) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Shire (NasdaqGS: SHPG) in a cash deal valued at approximately $4.2 billion. Under the terms of the proposed transaction, ViroPharma’s stockholders will receive $50.00 for each share of ViroPharma common stock they own.
The investigation focuses on whether ViroPharma’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether and by how much this proposed transaction undervalues the Company to the detriment of ViroPharma’s shareholders.
If you own common stock in ViroPharma and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.